Drug prescription in the elderly with diabetic in the first level of care
Abstract
Introduction: the treatment of diabetes mellitus in the elderly represents an important challenge for the prescription given the heterogeneity of this population group.
Objective: to identify the characteristics of the drugs prescription in the elderly with diabetes in the first level of health care.
Method: a study of medication use, retrospective longitudinal descriptive observational type in the "José Martí" Polyclinic of Santiago de Cuba was carried out during the first quarter of 2017. The universe was made up of 15 diabetic patients intentionally selected from an family medical office. The precepts of the II Declaration of Helsinki and the Cuban ethical regulations were fulfilled.
Results: type 2 diabetic (93,33 %), female sex (73,33 %) and age groups 60-64 and 65-69 years (33,33 % respectively) predominated. Cardiovascular disease prevailed as comorbidity in the only type 1 diabetic, and in 64,29 % of types 2, the use of glibenclamide (66,67 %), followed by metformin (26,67 %). In two patients (20,00 %) the indication of glibenclamide was inadequate. Potential interactions with other drugs consumed were identified in 30,00 % of those treated with glibenclamide, 25,00 % with metformin and the only one with insulin. High association of the antidiabetic with the following drugs was found: acetylsalicylic acid (73,33 %), non-steroidal anti-inflammatory drugs (66,67 %) and thiazide diuretics (60,00 %).
Conclusions: there was a rational prescription, although other pharmacological alternatives can be evaluated taking into account adverse effects, interactions and indicationsDownloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Leidys Cala Calviño, Tania Hernández Lin, Mileydis Álvarez Caballero, Liam Kadel Dunán Cruz, Deylis Jardines Cala, Sibelis Calderín Figueroa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The journal is not responsible for the opinions and concepts expressed in the works, which are the exclusive responsibility of the authors. The Editor, with the assistance of the Editorial Committee, reserves the right to suggest or request advisable or necessary modifications. Original scientific works are accepted for publication, as are the results of research of interest that have not been published or sent to another journal for the same purpose.
The mention of trademarks of specific equipment, instruments or materials is for identification purposes, and there is no promotional commitment in relation to them, neither by the authors nor by the editor.
